This was the stock's second consecutive day of losses.

Charles River Laboratories International Inc. closed 46.74% short of its 52-week high of $264.71, which the company reached ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take ...

Corebridge Financial Inc. lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 5.5% during the fourth quarter, according to its most recent disclosure ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to discover new molecules and potential therapies. Pfizer is partnering with ...

Learn more about whether Charles River Laboratories International, Inc. or Stevanato Group S.p.A. is a better investment ...

Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) have earned an average rating of ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial ...

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...